Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(1.91) per share which beat the analyst consensus estimate of $(2.27) by 15.67 percent. This is a 85.4 percent increase over losses of $(13.08) per share from the same period last year. The company reported quarterly sales of $169.000 thousand which missed the analyst consensus estimate of $800.000 thousand by 78.87 percent. This is a 72.11 percent decrease over sales of $606.000 thousand the same period last year.